Logan Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-18,511
Closed -$877K 453
2025
Q4
$942K Sell
18,511
-1,560
-8% -$79.8K 0.04% 213
2025
Q3
$1.11M Buy
20,071
+9,324
+87% +$546K 0.05% 206
2025
Q2
$742K Sell
10,747
-10,034
-48% -$683K 0.03% 218
2025
Q1
$1.44M Sell
20,781
-444
-2% -$36.7K 0.07% 193
2024
Q4
$1.83M Sell
21,225
-8,188
-28% -$885K 0.08% 184
2024
Q3
$3.5M Sell
29,413
-117
-0.4% -$15.6K 0.14% 143
2024
Q2
$4.22M Sell
29,530
-211
-0.7% -$28K 0.18% 125
2024
Q1
$3.82M Buy
29,741
+91
+0.3% +$10.8K 0.16% 135
2023
Q4
$3.07M Sell
29,650
-38
-0.1% -$3.76K 0.14% 150
2023
Q3
$2.7M Hold
29,688
0.14% 149
2023
Q2
$2.4M Hold
29,688
0.12% 162
2023
Q1
$2.36M Sell
29,688
-222
-0.7% -$15.7K 0.11% 163
2022
Q4
$2.02M Buy
29,910
+256
+0.9% +$15K 0.1% 170
2022
Q3
$1.48M Buy
29,654
+738
+3% +$39.5K 0.09% 182
2022
Q2
$1.61M Buy
28,916
+2,992
+12% +$166K 0.09% 180
2022
Q1
$1.44M Sell
25,924
-888
-3% -$45.6K 0.07% 190
2021
Q4
$1.5M Buy
26,812
+452
+2% +$24.5K 0.07% 197
2021
Q3
$1.26M Buy
26,360
+2,808
+12% +$136K 0.06% 206
2021
Q2
$986K Buy
23,552
+14,334
+156% +$556K 0.05% 215
2021
Q1
$311K Buy
+9,218
New +$328K 0.02% 260

Other funds holding NVO

Logan Capital Management's NVO Position: Q1 2026 in Review

Logan Capital Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 18,511 shares — an estimated $877K sold.

Logan Capital Management first reported a position in NVO in Q1 2021 and held it in 20 quarters. The position peaked at $4.22M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Logan Capital Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Logan Capital Management sold 18,511 Novo Nordisk shares in Q1 2026, an estimated $877K.
  • Logan Capital Management first reported a position in Novo Nordisk in Q1 2021 and held it in 20 quarters.
  • Logan Capital Management's Novo Nordisk position peaked at $4.22M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Logan Capital Management's 13F filing for Q1 2026, filed 8 May 2026.